3 December 2023 in Clinical and Translational Radiation Oncology
The PRIDE trial (NOA-28; ARO-2022-12; NCT05871021) is scheduled to start recruitment in October 2023. Its primary objective is to enhance median overall survival (OS), compared to historical median OS rates, in patients with methylguanine methlyltransferase (MGMT) promotor unmethylated glioblastoma by incorporating isotoxic dose escalation to 75 Gy in 30 fractions. To achieve isotoxicity and counteract the elevated risk of radiation necrosis (RN) associated with dose-escalated regimens, the addition of protective concurrent bevacizumab (BEV) serves as an innovative approach. The current study aims to assess the dosimetric feasibility of the proposed concept. A total of ten patients diagnosed with glioblastoma were included in this dosimetric analysis. Delineation of target volumes for the reference plans adhered to the ESTRO-EANO 2023 guideline. The experimental plans included an additional volume for the integrated boost. Additionally, the 60 Gy-volume was reduced by using a margin of 1.0 cm instead of 1.5 cm. To assess the risk of symptomatic RN, the Normal Tissue Complication Probability (NTCP) was calculated and compared between the reference and experimental plans. Median NTCP of the reference plan (NTCPref) and of the experimental plan (NTCPex) were 0.24 (range 0.11–0.29) and 0.42 (range 0.18–0.54), respectively. NTCPex was a median of 1.77 (range 1.60–1.99) times as high as the NTXPref. In a logarithmic comparison, the risk of RN is enhanced by a factor of median 2.00 (range 1.66–2.35). The defined constraints for the organs at risk were feasible. When considering the potential protective effect of BEV, which we hypothesized might reduce the risk of RN by approximately two-fold, achieving isotoxicity with the proposed dose-escalated experimental plan for the PRIDE trial seems feasible.
4 May 2024 in Clinical and Translational Radiation Oncology
The PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06; NCT05871021) is designed to determine whether a dose escalation with 75.0 Gy in 30 fractions can enhance the median overall survival (OS) in patients with methylguanine methyltransferase (MGMT) promotor unmethylated glioblastoma compared to historical median OS rates, while being isotoxic to historical cohorts through the addition of concurrent bevacizumab (BEV). To ensure protocol-compliant irradiation planning with all study centers, a dummy run was planned and the plan quality was evaluated. A suitable patient case was selected and the computed tomography (CT), magnetic resonance imaging (MRI) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) contours were made available. Participants at the various intended study sites performed radiation planning according to the PRIDE clinical trial protocol. The treatment plans and dose grids were uploaded as Digital Imaging and Communications in Medicine (DICOM) files to a cloud-based platform. Plan quality and protocol adherence were analyzed using a standardized checklist, scorecards and indices such as Dice Score (DSC) and Hausdorff Distance (HD). Median DSC was 0.89, 0.90, 0.88 for PTV60, PTV60ex (planning target volume receiving 60.0 Gy for the standard and the experimental plan, respectively) and PTV75 (PTV receiving 75.0 Gy in the experimental plan), respectively. Median HD values were 17.0 mm, 13.9 mm and 12.1 mm, respectively. These differences were also evident in the volumes: The PTV60 had a volume range of 219.1–391.3 cc (median: 261.9 cc) for the standard plans, while the PTV75 volumes for the experimental plans ranged from 71.5–142.7 cc (median: 92.3 cc). The structures with the largest deviations in Dice score were the pituitary gland (median 0.37, range 0.00–0.69) and the right lacrimal gland (median 0.59, range 0.42–0.78). The deviations revealed the necessity of systematic trainings with appropriate feedback before the start of clinical trials in radiation oncology and the constant monitoring of protocol compliance throw-out the study. NCT05871021
1 December 2025 in medRxiv
ProKnow is an archive and restore tool for radiation oncology and imaging data, peer review, distributed contouring, study of metrics and discovery of trends; it represents a common ground for plan analysis and comparison due to an integrated industry standard Dose-Volume Histogram (DVH) engine, which can be used for all patient datasets. The aim of this work is to present a deep and easy-to-use implementation of the Elekta ProKnow DS cloud-based Picture Archiving and Communications in Radiotherapy (RT-PACS) system within our department. Two de-identification workflows of the DICOM data are presented, the first one is accomplished via the ProKnow Dicom Agent (PDA) and the second one involves a trusted third-party service. We can access ProKnow not only through the user interface, but also through the Application Programming Interface (API) with scripts written in the Python language to extract information from the uploaded data, calculate and store metrics as well as upload clinical data. We used ProKnow for a retrospective feasibility study of an isotoxic dose-escalated radiotherapy concept for glioblastoma. Furthermore, to ensure protocol-compliant irradiation planning for the preparation of a prospective dose-escalation trial, we conducted a dummy run with 10 collaborating institutes in Germany. RT-structures were automatically downloaded (via the API) and the Dice Score and Hausdorff Distance were calculated and set as metric in ProKnow. A drawback of the currently implemented de-identification process is that in a subsequent clinical data upload, matching the original and de-identified IDs is not possible. We therefore collaborate with the MeDIC LMU (Data Integration Center [DIC]) for development and implementation of an automated de-identification process via a trusted third party service. With this architecture, it will be possible to merge clinical data in local DIC databases with de-identified data in ProKnow at any point in time. Author Summary: Until now, it has been difficult to make scientific comparisons of treatments in radiation oncology because complex dose-volume distributions have to be compared rather than point doses at an isocentre, as is often thought. For the first time, ProKnow software enables the manufacturer-independent comparison of dose-volume distributions in tumour and normal tissue for large cohorts. With the above-described integration, multicentre research with state-of-the-art, secure, cloud-based data flows becomes easy to use.
17 July 2026 in PLOS Digital Health
ProKnow is an archive and restore tool for radiation oncology and imaging data, peer review, distributed contouring, study of metrics and discovery of trends; it represents a common ground for plan analysis and comparison due to an integrated industry standard Dose-Volume Histogram (DVH) engine, which can be used for all patient datasets. The aim of this work is to present a deep and easy-to-use implementation of the Elekta ProKnow DS cloud-based Picture Archiving and Communications in Radiotherapy (RT-PACS) system within our department. Two de-identification workflows of the DICOM data are presented, the first one is accomplished via the ProKnow Dicom Agent (PDA) and the second one involves a trusted third-party service. We can access ProKnow not only through the user interface, but also through the Application Programming Interface (API) with scripts written in the Python language to extract information from the uploaded data, calculate and store metrics as well as upload clinical data. A drawback of the currently implemented de-identification process is that in a subsequent clinical data upload, matching the original and de-identified IDs is not possible. To mitigate this drawback, we collaborate with the MeDIC LMU (Data Integration Center [DIC]) for development and implementation of an automated de-identification process via a trusted third party service. With this architecture, it will be possible to merge clinical data in local DIC databases with de-identified data in ProKnow at any point in time, facilitating the longitudinal outcomes analysis. We used ProKnow for a retrospective dosimetric feasibility study of an isotoxic dose-escalated radiotherapy proof-of-concept for glioblastoma. Furthermore, to ensure protocol-compliant irradiation planning for the preparation of a prospective dose-escalation trial, we conducted a dummy run with 10 collaborating institutes in Germany. RT-structures were automatically downloaded (via the API) and the Dice Score and Hausdorff Distance were calculated and set as metric in ProKnow.